Prosecution Insights
Last updated: April 17, 2026
Application No. 18/390,313

WASHING AND/OR DISINFECTING AGENTS AND METHOD OF USING SAME

Non-Final OA §102§112
Filed
Dec 20, 2023
Examiner
COHEN, MICHAEL P
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
unknown
OA Round
1 (Non-Final)
58%
Grant Probability
Moderate
1-2
OA Rounds
2y 11m
To Grant
86%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allow Rate
484 granted / 829 resolved
-1.6% vs TC avg
Strong +28% interview lift
Without
With
+27.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
48 currently pending
Career history
877
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
55.3%
+15.3% vs TC avg
§102
7.3%
-32.7% vs TC avg
§112
7.7%
-32.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 829 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim Status Claims 1-9 are pending and are examined on the merits in this prosecution. Claim Objections Claim 4, second line, the term “bae” appears to be a misspelling of the word “base.” Claim 5, first line, recites the term “the dye in phenolphthalein.” It is believed the term “in” should be “is”. Claim 6, second line, recites the term “o”. It is unclear what this term or letter signifies or suggests. Claim 7, third line, has two consecutive commas. Appropriate corrections are required. CLAIM REJECTIONS Indefiniteness Rejections The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claims 1-9 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claim 1, second line, recites the term “especially of surfaces in the medical field and/or skin surfaces.” As discussed in MPEP 2173.05(d), “Description of examples or preferences is properly set forth in the specification rather than the claims. If stated in the claims, examples and preferences may lead to confusion over the intended scope of a claim. In those instances where it is not clear whether the claimed narrower range is a limitation, a rejection under 35 U.S.C. 112(b) or pre-AIA 35 U.S.C. 112, second paragraph should be made.” Claim 1, sixth line, and claim 9, sixth line each recite the term “color consistency.” The term “color consistency” typically refers to the appearance of a color when measured against a standard or expectation. Such a standard is not set forth in the Specification, and therefore the metes and bounds of the term cannot be determined. Claim 1, seventh line, recites the term “a predeterminable period of time.” It is unclear from the instant specification what this period of time is or how it is controlled. As such, the claim language is considered indefinite since the metes and bounds of the claim cannot be determined. See MPEP 2173.02. Claim 2, third line, recites the term “a predetermined amount.” This term is unclear since an amount is not recited in the claim, and the term is not found in the Specification. Further regarding claim 2, it is unclear how much indicator additive is being added since is it unclear what is meant by the term “the indicator additive (3) is admixed with at least 3% by volume, and/or 3 mol% of the base composition (2).” Claim 6, third line recites the terms “viscous liquid” and “non-viscous liquid.” The term “viscous” is considered a relative term, and the instant Specification provides no standard for measuring the degrees intended. See MPEP 2173.05(b). Claim 8, second line, and claim 9, fourth line, each recites the term “including skin surfaces.” As discussed above, description of examples or preferences is properly set forth in the specification rather than the claims. If stated in the claims, examples and preferences may lead to confusion over the intended scope of a claim. Anticipation Rejections The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. 1) Claims 1-3 and 6-9 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Gleissner (US 2022/0195353 A1, filed 06/03/2021; the alternatively spelled Gleißner, is considered the same inventor wherein the ‘353 application recites the German eszett “ß” for “ss”). For claim 1, Gleissner teaches the following (pg 2, claim 1): PNG media_image1.png 378 605 media_image1.png Greyscale For claim 2, Gleissner teaches the following (pg 2, claim 2): PNG media_image2.png 190 538 media_image2.png Greyscale For claim 3, Gleissner teaches the following (pg 2, claim 3): PNG media_image3.png 144 548 media_image3.png Greyscale For claim 6, Gleissner teaches the following (pg 2, claim 4): PNG media_image4.png 143 543 media_image4.png Greyscale For claim 7, Gleissner teaches the following (pg 2, claim 5): PNG media_image5.png 247 556 media_image5.png Greyscale For claims 8-9, Gleissner teaches the following (pg 2, claim 7): PNG media_image6.png 386 600 media_image6.png Greyscale 2) Claims 1-9 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by McDonald (US 2005/0065048 A1). MacDonald teaches a liquid soap containing and indicator wherein the user washes their hands and a color change occurs (Abstract; pf 4, [0041]; claims 1-3). This appears to be identical to the invention claimed. As the reference uses a fluorescent red dye, the examiner maintains the "generates light" limitation is satisfied. As this reference meets all material limitations of the claims at hand, the reference is anticipatory. With respect to claim 2, as it is impossible to know what is meant by a "predetermined amount" the examiner maintains this limitation is satisfied. For claim 4, MacDonald teaches a “soap,” by definition a metal salt. For claim 5, MacDonald teaches a “phenolphthalein” as a dye indicator ([0041]). For claim 6, MacDonald teaches liquid soaps (pg 4, [0038]-[0041]). For claim 7, MacDonald teaches (pg 1, [0008]): PNG media_image7.png 93 444 media_image7.png Greyscale PNG media_image8.png 124 453 media_image8.png Greyscale For claims 8-9, MacDonald teaches the method of making the product for the washing of hands and body (pg 1, [0002]) requires the following steps (pg 2, [0022]): PNG media_image9.png 368 444 media_image9.png Greyscale 3) Claims 1-9 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by VInson (US 2014/0057987 A1). Vinson teaches compositions comprising a disinfectant, a pH indicator dye, and an alkaline Substance. The pH indicator dye expresses a color when initially sprayed, but loses or changes color once sprayed. The compositions may be used to disinfect surfaces, and the pH indicator dye indicates what surface has been disinfected and ensures that a sufficient period of time has passed to disinfect the surface (Abstract). Vinson teaches the surface may be skin (pg 3, [0033]). With respect to claim 2, as it is impossible to know what is meant by a "predetermined amount" the examiner maintains this limitation is satisfied. For claim 3, Vinson teaches specific indicators that change color once sprayed (pg 5, [0062]); for claim 5, the table in ¶ [0062] recites phenolphthalein. For claim 4, Vinson teaches the disinfectant may be an alcohol, an aldehyde, an oxidizing agent, a phenol, or a quaternary ammonium surfactant (pg 8, claim 7). For claim 6, Vinson teaches the composition may be a liquid (pg 3, [0040]) or gel (pg 3, [0041]; pgs 7-8, Example 2). For claim 7, Vinson teaches (pg 2, [0021] and [0030]): PNG media_image10.png 113 453 media_image10.png Greyscale and PNG media_image11.png 402 467 media_image11.png Greyscale For claims 8 and 9, Vinson teaches addition of the claimed elements to a bottle containing a pump for distribution to a skin surface (pgs 7-8, Examples 1 and 2; pg 3, [0033]; pg 4, [0050]). CONCLUSION Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL P COHEN whose telephone number is (571)270-7402. The examiner can normally be reached on M-Th 8:30-5:30; F 9-4. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana S. Kaup, can be reached on (571) 272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL P COHEN/Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Dec 20, 2023
Application Filed
Jan 22, 2026
Non-Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600990
mRNA INDUCED EXPRESSION OF BONE MORPHOGENIC PROTEIN AND RECEPTOR AND METHODS RELATED THERETO
2y 5m to grant Granted Apr 14, 2026
Patent 12582608
COATINGS FOR GASTRIC RESIDENCE DOSAGE FORMS
2y 5m to grant Granted Mar 24, 2026
Patent 12582581
LAMINATE SHEET FOR COSMETIC, AND COSMETIC SET
2y 5m to grant Granted Mar 24, 2026
Patent 12582669
COMPOSITION CONTROLLING PHARMACOKINETICS IN THE BODY
2y 5m to grant Granted Mar 24, 2026
Patent 12576037
POLYMER-ENCAPSULATED DRUG PARTICLES
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
58%
Grant Probability
86%
With Interview (+27.6%)
2y 11m
Median Time to Grant
Low
PTA Risk
Based on 829 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in for Full Analysis

Enter your email to receive a magic link. No password needed.

Free tier: 3 strategy analyses per month